

PEDIATRIX MEDICAL GROUP INC

Form 8-K

August 14, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities and Exchange Act of 1934**

**Date of Report (date of earliest event reported): August 11, 2006**

**PEDIATRIX MEDICAL GROUP, INC.**

**(Exact Name of Registrant as Specified in Its Charter)**

**Florida**

**001-12111**

**65-0271219**

**(State or Other Jurisdiction  
of Incorporation)**

**(Commission File  
Number)**

**(IRS Employer  
Identification No.)**

**1301 Concord Terrace Sunrise, Florida 33323**

**(Address of principal executive office)**

**Registrant's telephone number, including area code ~~(954) 384-0175~~**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement.**

On August 11, 2006, Pediatrix Medical Group, Inc. (the Company), certain of the Company's subsidiaries and affiliates (collectively with the Company, the Borrowers), Bank of America, N.A. (the Administrative Agent), and each of the lenders signatory thereto entered into a Consent to Extension Agreement (the Consent). Pursuant to Sections 6.01(b) and 6.02(b) of the Credit Agreement dated as of July 30, 2004 among the Borrowers, the Administrative Agent and each of the lenders signatory thereto as previously amended through the date hereof (the Credit Agreement), the Company is required to deliver to the Administrative Agent quarterly financial statements (the Quarterly Financial Statements) and a compliance certificate (the Compliance Certificate) as soon as available, but in any event within 45 days after the end of each of the first three fiscal quarters of the Company's fiscal year. The Consent provides an extension of time for the delivery of the Quarterly Financial Statements and Compliance Certificate required for the fiscal quarter ended June 30, 2006 until October 15, 2006.

The foregoing description of the Consent does not purport to be complete and is qualified in its entirety by reference to the full text of such Consent, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference thereto.

**ITEM 9.01 Financial Statements and Exhibits**

*(d) Exhibits.*

10.1 Consent to Extension Agreement dated August 11, 2006.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PEDIATRIX MEDICAL GROUP, INC.**

Date: August 14, 2006

By: /s/ Karl B. Wagner

Name: Karl B. Wagner

Title: Chief Financial Officer

3

---

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
10.1	Consent to Extension Agreement dated August 11, 2006.

4